Patient‐Reported Outcomes With First‐Line Immunotherapy‐Based Combination Treatment for Advanced Lung Cancer: A Prospective, Multicenter, Observational Study
Thoracic Cancer · 2025
DOI: 10.1111/1759-7714.70155 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Thoracic Cancer, 2025. Verfasst von Rong Jia und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated…. Hauptthemen laut MEDLINE: Patient Reported Outcome Measures, Lung Neoplasms, Immunotherapy, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Guangdong Association of Clinical Trials (GACT)/Chinese Thoracic Oncology Group (CTONG) and Guangdong Provincial Key Lab of Translational Medicine in Lung Canc…, 2022CSCO key program, Construction of the whole process management and rehabilitation evaluation system of immunotherapy for advanced lung cancer based on patient-reported outcomes….
Abstract (Originalsprache)
Background
This study aimed to characterize longitudinal trajectories of tumor burden and treatment‐related symptoms following immune checkpoint inhibitor (ICI) therapy in patients with advanced lung cancer, based on electronic patient‐reported outcomes (ePRO).
Methods
Using the MD Anderson Symptom Inventory‐Lung Cancer module and an immune‐related adverse event symptom item scale, we collected the ePRO data of patients undergoing first‐line immunotherapy‐based combination treatment for advanced unresectable primary lung cancer. Evaluating trajectories of primary symptoms and symptom differences between treatment groups using linear mixed‐effects models.
Results
A total of 168 patients were included in the study. The top five symptoms with the highest severity before treatment were coughing, distress, shortness of breath, disturbed sleep, and pain. Coughing was gradually attenuated with ongoing treatment. Symptoms of distress, shortness of breath, disturbed sleep, and pain also showed an overall decreasing trend. The top five immunotherapy‐related symptoms, with the highest severity, were early satiety, abdominal distension, night sweats, altered sense of taste, and bloated pain, which demonstrated a cyclical gradual increase throughout treatment. Compared to the ICIs + chemotherapy group, the ICIs + chemotherapy + VEGFR‐TKIs group showed significantly lower burden in four of the top five immunotherapy‐related symptoms, with the exception of night sweats, which demonstrated no significant difference.
Conclusions
Patients with advanced lung cancer experienced reduced severity of lung cancer‐related symptoms after receiving immunotherapy‐based combination treatment, and immune‐specific symptoms showed cyclical exacerbation with ongoing treatment. The addition of VEGFR‐TKIs to ICIs + chemotherapy did not increase the associated toxicity burden.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of…
- Chengdu Shuangliu Hospital of Traditional Chinese Medicine, Chengdu, China.
- Sichuan Provincial People's Hospital East Sichuan Hospital and Dazhou First People's Hospital, Dazhou, China.
- Cancer Center, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
- Department of Medical Oncology, The Third People's Hospital of Chengdu, Chengdu, China.
- Department of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of…
ORCID-Profile: Junyi Zou, Fan Yang, Wei Dai, Xing Wei, Qiuling Shi
Förderung
- Guangdong Association of Clinical Trials (GACT)/Chinese Thoracic Oncology Group (CTONG) and Guangdong Provincial Key Lab of Translational Medicine in Lung Canc…
- 2022CSCO key program
- Construction of the whole process management and rehabilitation evaluation system of immunotherapy for advanced lung cancer based on patient-reported outcomes…
Zitieren
APA
Jia, R., Zou, J., Hu, H., Wang, X., Zheng, Y., Yang, F., Pang, Y., Wang, K., Wang, Y., Tang, J., Kou, L., Liu, Y., Ding, J., Li, X., Dai, W., Wei, X., Shi, Q., & Zhou, J. (2025). Patient‐Reported Outcomes With First‐Line Immunotherapy‐Based Combination Treatment for Advanced Lung Cancer: A Prospective, Multicenter, Observational Study. Thoracic Cancer. https://doi.org/10.1111/1759-7714.70155
Vancouver
Jia R, Zou J, Hu H, Wang X, Zheng Y, Yang F, et al. Patient‐Reported Outcomes With First‐Line Immunotherapy‐Based Combination Treatment for Advanced Lung Cancer: A Prospective, Multicenter, Observational Study. Thoracic Cancer. 2025. doi:10.1111/1759-7714.70155
BibTeX
@article{Jia2025,
author = {Jia, Rong and Zou, Junyi and Hu, Han and Wang, Xiaoshan and Zheng, Yuzhu and Yang, Fan and Pang, Yan and Wang, Ke and Wang, Yi and Tang, Jianning and Kou, Lingna and Liu, Yang and Ding, Jing and Li, Xin and Dai, Wei and Wei, Xing and Shi, Qiuling and Zhou, Jin},
title = {Patient‐Reported Outcomes With First‐Line Immunotherapy‐Based Combination Treatment for Advanced Lung Cancer: A Prospective, Multicenter, Observational Study},
journal = {Thoracic Cancer},
year = {2025},
doi = {10.1111/1759-7714.70155}
}
EUVIMED